Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04348305|
Recruitment Status : Recruiting
First Posted : April 16, 2020
Last Update Posted : May 13, 2020
|Condition or disease||Intervention/treatment||Phase|
|Covid-19 Hypoxia||Drug: Hydrocortisone Drug: Sodium Chloride 9mg/mL||Phase 3|
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic of coronavirus disease (COVID-19) with many patients developing severe hypoxic respiratory failure. Many patients have died, and healthcare systems in several countries have been or will be overwhelmed because of a surge of patients needing hospitalisation and intensive care. There is no proven treatment for COVID-19; the care is supportive, including respiratory and circulatory support. For other patient groups with similar critical illness (acute respiratory disease syndrome and septic shock), corticosteroids are used because they reduce the duration of mechanical ventilation, length of stay in the intensive care unit, and potentially also mortality. Corticosteroids have been used in some patients with COVID-19, but the recommendations in clinical guidelines differ; some suggest their use, others against.
Objectives: We aim to assess the effects of low-dose intravenous hydrocortisone on the number of days alive without life-support in adult patients with COVID-19 and severe hypoxia.
Design: Multicentre, parallel-group, centrally randomised, stratified, blinded, clinical trial.
Population: Adult patients with documented COVID-19 receiving at least 10 L/min of oxygen independent of delivery system OR mechanical ventilation.
Experimental intervention: Continuous IV infusion of hydrocortisone 200 mg daily will be given for 7 days in addition to standard care.
Control intervention: Continuous IV infusion of matching placebo (0.9% saline) will be given in addition to standard care (no corticosteroids).
Outcomes: The primary outcome is days alive without life support (i.e. mechanical ventilation, circulatory support, or renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions (i.e. anaphylactic reaction to hydrocortisone, new episode of septic shock, invasive fungal infection or clinically important gastrointestinal bleeding); days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90 and 1 year; and health-related quality of life at 1 year.
Sample size: A total of 1000 participants will be randomised in order to detect a 15% relative reduction in 28-day mortality combined with a 10% reduction in time on life support among the survivors with a power of 85%.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial|
|Actual Study Start Date :||April 17, 2020|
|Estimated Primary Completion Date :||March 30, 2021|
|Estimated Study Completion Date :||December 30, 2021|
Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care.
If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours).
Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
Other Name: Solu-cortef
Placebo Comparator: Isotonic Saline
Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment).
If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours).
Drug: Sodium Chloride 9mg/mL
Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
Other Name: Isotonic saline
- Days alive without life support at day 28 [ Time Frame: Day 28 after randomisation ]Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28
- All-cause mortality at day 28 [ Time Frame: Day 28 after randomisation ]Death from all causes
- Days alive without life support at day 90 [ Time Frame: Day 90 after randomisation ]Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90
- All-cause mortality at day 90 [ Time Frame: Day 90 after randomisation ]Death from all causes
- Number of participants with one or more serious adverse reactions [ Time Frame: Day 14 after randomisation ]Defined as new episodes of septic shock, invasive fungal infection, clinically important GI bleeding or anaphylactic reaction
- Days alive and out of hospital at day 90 [ Time Frame: Day 90 after randomisation ]Number of days alive and out of hospital not limited to the index admission
- All-cause mortality at 1 year after randomisation [ Time Frame: 1 year after randomisation ]Death from all causes
- Health-related quality of life at 1 year [ Time Frame: 1 year after randomisation ]Assessed by EQ-5D-5L
- Health-related quality of life at 1 year [ Time Frame: 1 year after randomisation ]Assessed by EQ-VAS
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04348305
|Contact: Marie Warrer Petersen, MD||+45 3545 email@example.com|
|Contact: Maj-brit N Kjær, RN, MSc||+45 35457236||Maj-Brit.Noerregaard.Kjaer@regionh.dk|
|Aarhus University Hospital - Dept of Intensive care||Recruiting|
|Contact: Steffen Christensen|
|Copenhagen, Denmark, DK-2100|
|Contact: Anders Perner 35458333 firstname.lastname@example.org|
|Herlev Hospital - Dept. of Intensive Care||Recruiting|
|Contact: Anne S Andreasen email@example.com|
|North Zealand Hospital||Recruiting|
|Contact: Morten Bestle Morten.Bestle@regionh.dk|
|Hvidovre Hospital - Dept of Infectious diseases||Recruiting|
|Contact: Thomas Benfield Thomas.Lars.Benfield@regionh.dk|
|Hvidovre Hospital - Dept of Intensive Care||Recruiting|
|Contact: Klaus T Kristiansen firstname.lastname@example.org|
|Hvidovre Hospital - Dept of Pulmonary Medicine||Recruiting|
|Contact: Charlotte S Ulrik Charlotte.Suppli.Ulrik@regionh.dk|
|Contact: Anne C Brøchner Anne.Craveiro.Broechner@rsyd.dk|
|Contact: Lone M Poulsen email@example.com|
|Contact: Thomas Hildebrandt|
|Contact: Anders Møller firstname.lastname@example.org|
|Contact: Christoffer Sølling email@example.com|
|Study Chair:||Anders Perner, MD, PhD||Rigshospitalet, Denmark|